We continue the momentum for a di🍷versified innovation by༒ enhancing internal innovation capacities and reaching out to more strategic partners. We have been replenishing our innovation pipeline with HANSIZHUANG (serplulimab injection, anti-PD-1 mAb) as backbone.
Fully leveraging the global research and development platform, we have been exploring pipeline opportunities for more than 20 innovative mAb candidates, with significant🔴 potential for a variety of PD-1-based immuno-oncology combination therapies.
We have 3 manufacturing facilities, namely Xuhui Facility, Songjiang First Plant and Songjiang Second Plant. Our commercial capacity totals 48,000L for now with an estimate of 144,000L in 2026. Xuhui 🗹Facility and Songjiang First Plant are both certificated by China and the EU Good Manufacturing Practice (GMP).
We have built an in-house commercial team focused on domestic market, covering marketi🌳ng, access, channel, pricing, strategy and sales and compromising of about 450 professionals; we have also joined fo🍌rces with oversea partners, expanding our reach in major markets as well as emerging markets worldwide.
